BridgeBio Pharma, Inc.BBIONASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+21.2%
5Y CAGR+16.7%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+21.2%/yr
vs +33.7%/yr prior
5Y CAGR
+16.7%/yr
Recent acceleration
Acceleration
-12.5pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.2x
Strong expansion
Streak
3 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $1.04B | +28.6% |
| 2024 | $811.00M | +32.0% |
| 2023 | $614.23M | +4.7% |
| 2022 | $586.42M | -8.8% |
| 2021 | $643.23M | +33.2% |
| 2020 | $482.73M | +58.6% |
| 2019 | $304.30M | +65.7% |
| 2018 | $183.66M | +318.8% |
| 2017 | $43.86M | - |